 |
|
| TARGET VALIDATION IN DRUG DISCOVERY
| |
| | |
|
|
To order this title, and for more information, click here
Edited By
Brian Metcalf, Chief Drug Discovery Officer, Incyte Corporation, Moraga, CA, U.S.A.
Susan Dillon, Senior Vice President, Discovery Research Centocor, Johnson & Johnson, Malvern, PA, U.S.A.
Description
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed
description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section
looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and
Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics,
present new possible small molecule therapeutics and serve as the focus of the final section of the book.
Audience
Professionals in biotechnology and pharmaceutical drug discovery and clinical development. Can also include students and academics in the related areas of study.
Contents
Section Contents
I. Pharmaceutical Biotechnology for Target Validation
II. Target Validation for Biopharmaceutical Drug Discovery
III. Validating Targets of Small Molecule Approaches
| Bibliographic details |
Hardbound, 296 pages, publication date: SEP-2006
ISBN-13: 978-0-12-369393-8
ISBN-10: 0-12-369393-4
Imprint: ACADEMIC PRESS
|
| Price and Ordering |
Price:
EUR 70.95
GBP 60
USD 94.95
|  |
Books and book related electronic products are priced in US dollars (USD), euro (EUR), and Great Britain Pounds (GBP). USD prices apply to the Americas and Asia Pacific. EUR prices apply in Europe and the Middle East. GBP prices apply to the UK and all other countries.
|
See also information about conditions of sale & ordering procedures, and links to our regional sales offices.
|
090/951
Last update: 5 Sep 2009
|
|
| |
| | |
|
|
| |
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company